ACADIA Pharmaceuticals Inc. (ACAD) Financial Statements
ACADIA Pharmaceuticals Inc. (ACAD) reported trailing twelve-month revenue of $1.1B (up 11.8% year on year) and net income of $380.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $145.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACADACADIA Pharmaceuticals Inc.Follow ACAD — free
—
Price chart with a free account
- Market cap
- 3.4B
- P/E TTM
- 8.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.12 | 0.22 | 0.34 | 0.44 | 0.48 | 0.52 | 0.73 | 0.96 | 1.07 | 1.14 | |
| Gross profit | — | — | — | — | — | 0.01 | 0.12 | 0.21 | 0.33 | 0.43 | 0.47 | 0.51 | 0.68 | 0.88 | 0.98 | 1.04 | |
| Research & development | 0.02 | 0.02 | 0.03 | 0.06 | 0.07 | 0.10 | 0.15 | 0.19 | 0.24 | 0.32 | 0.24 | 0.36 | 0.35 | 0.30 | 0.33 | 0.33 | |
| Operating income | -0.02 | -0.02 | -0.04 | -0.09 | -0.16 | -0.27 | -0.29 | -0.25 | -0.25 | -0.29 | -0.17 | -0.22 | -0.07 | 0.23 | 0.10 | 0.09 | |
| Pre-tax income | -0.02 | -0.02 | -0.04 | -0.09 | -0.16 | -0.27 | -0.29 | -0.24 | -0.23 | -0.28 | -0.17 | -0.21 | -0.05 | 0.26 | 0.14 | 0.12 | |
| Income tax | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | -0.25 | -0.26 | |
| Net income | -0.02 | -0.02 | -0.04 | -0.09 | -0.16 | -0.27 | -0.29 | -0.25 | -0.24 | -0.28 | -0.17 | -0.22 | -0.06 | 0.23 | 0.39 | 0.38 | |
| Diluted EPS ($) | -0.44 | -0.38 | -0.44 | -0.95 | -1.63 | -2.34 | -2.36 | -1.94 | -1.60 | -1.79 | -1.05 | -1.34 | -0.37 | 1.36 | 2.30 | 2.23 | |
| Diluted shares (bn) | 0.052 | 0.055 | — | — | — | — | — | — | — | 0.157 | 0.160 | 0.162 | 0.164 | 0.166 | 0.170 | — |
USD billions · SEC XBRL
ACADIA Pharmaceuticals Inc. — questions
- What is ACADIA Pharmaceuticals Inc.'s revenue?
- $1.1B over the twelve months to 2026-06-30, up 11.8% year on year, from its 10-Q and 10-K filings.
- What is ACADIA Pharmaceuticals Inc.'s net income?
- $380.5M over the twelve months to 2026-06-30.
- What is ACADIA Pharmaceuticals Inc.'s free cash flow?
- $145.6M over the twelve months to 2026-06-30.
- What are ACADIA Pharmaceuticals Inc.'s diluted earnings per share?
- $2.23 over the twelve months to 2026-06-30.
Every figure on this page comes from ACADIA Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.